Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CRN priorities for CFSAN

This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition asks FDA to prioritize providing guidance and conducting stakeholder meetings with industry on implementing the dietary supplement good manufacturing practices final rule, CRN says in comments submitted Aug. 29. Other CRN recommendations include FDA adding reviewers to expedite the Center for Food Safety and Applied Nutrition's evaluation of adverse event reports, which supplement and OTC firms will be required to submit beginning in December under the AER law Congress enacted in 2006, and to amend the MedWatch form to include space to indicate whether consumers say they will allow their physicians to speak with firms' medical representatives (1"The Tan Sheet" Aug. 20, 2007, p. 13)...

You may also be interested in...

AHPA Asks FDA To Allow Firms To Route AER Contact To Offices Outside U.S.

FDA's guidance on adverse event reporting for OTC drugs and dietary supplements should assure that firms operating outside the country can use U.S. addresses on their product labels but receive AER-related communication in their home countries, the American Herbal Products Association recommends

Bharat Biotech Gets Shot In Arm With 81% Efficacy For COVID-19 Vaccine

Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.

Australia’s Manufacturing Road Map Wins Plaudits From Industry

A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts